bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 GSEA Analysis from ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage
Authors: Perkhofer Lukas , Schmitt Anna , Romero Carrasco Maria Carolina , Ihle Michaela , Hampp Stephanie , Ruess Dietrich Alexander , Hessmann Elisabeth , Russell Ronan , Lechel André , Azoitei Ninel , Lin Qiong , Liebau Stefan , Hohwieler Meike , Bohnenberger Hanibal , Lesina Marina , Algül Hana , Gieldon Laura , Schröck Evelin , Gaedcke Jochen , Wagner Martin , Wiesmüller Lisa , Sipos Bence , Seufferlein Thomas , Reinhardt Hans Christian , Frappart Pierre-Olivier , Kleger Alexander
Published: April 2023

GSEA Analysis
Supplemental Material - Group Authorship from EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas
Authors: Etemadmoghadam Dariush , Azar Walid J. , Lei Ying , Moujaber Tania , Garsed Dale W. , Kennedy Catherine J. , Fereday Sian , Mitchell Chris , Chiew Yoke-Eng , Hendley Joy , Sharma Raghwa , Harnett Paul R. , Li Jason , Christie Elizabeth L. , Patch Ann-Marie , George Joshy , Au-Yeung George , Mir Arnau Gisela , Holloway Timothy P. , Semple Timothy , Pearson John V. , Waddell Nicola , Grimmond Sean M. , Köbel Martin , Rizos Helen , Lomakin Ivan B. , Bowtell David D.L. , deFazio Anna
Published: April 2023

Supplemental Material - Group Authorship from EIF1AX and NRAS Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas
Figure S3 from ETV1-Positive Cells Give Rise to BRAFV600E-Mutant Gastrointestinal Stromal Tumors
Authors: Ran Leili , Murphy Devan , Sher Jessica , Cao Zhen , Wang Shangqian , Walczak Edward , Guan Youxin , Xie Yuanyuan , Shukla Shipra , Zhan Yu , Antonescu Cristina R. , Chen Yu , Chi Ping
Published: April 2023

Combination of heterozygous BrafV600E activation and Trp53 loss induced ICChyperplasias in stomach and cecum, but not in small intestine.
Table S1 from Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer
Authors: Zhang Dongmei , Zhang Gao , Hu Xiaowen , Wu Lawrence , Feng Yi , He Sidan , Zhang Youyou , Hu Zhongyi , Yang Lu , Tian Tian , Xu Weiting , Wei Zhi , Lu Yiling , Flaherty Keith T. , Zhong Xiaomin , Mills Gordon B. , Gimotty Phyllis A. , Xu Xiaowei , Herlyn Meenhard , Zhang Lin
Published: April 2023

Table S1: Cell lines used in the current study
Figure S1 from Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer
Authors: Zhang Dongmei , Zhang Gao , Hu Xiaowen , Wu Lawrence , Feng Yi , He Sidan , Zhang Youyou , Hu Zhongyi , Yang Lu , Tian Tian , Xu Weiting , Wei Zhi , Lu Yiling , Flaherty Keith T. , Zhong Xiaomin , Mills Gordon B. , Gimotty Phyllis A. , Xu Xiaowei , Herlyn Meenhard , Zhang Lin
Published: April 2023

Figure S1. The oncogenic RAS-regulated lncRNAs were identified by a custom-designed microarray
Supp Figure 5 from Nuclear CD24 Drives Tumor Growth and Is Predictive of Poor Patient Prognosis
Authors: Duex Jason E. , Owens Charles , Chauca-Diaz Ana , Dancik Garrett M. , Vanderlinden Lauren A. , Ghosh Debashis , Leivo Mariah Z. , Hansel Donna E. , Theodorescu Dan
Published: April 2023

Additional cancer patient datasets showing the nucCD24 gene signature correlates negatively with survival
Supplemental Figure 6 from Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
Authors: Abu Eid Rasha , Ahmad Shamim , Lin Yuan , Webb Mason , Berrong Zuzana , Shrimali Rajeev , Kumai Takumi , Ananth Sudha , Rodriguez Paulo C. , Celis Esteban , Janik John , Mkrtichyan Mikayel , Khleif Samir N.
Published: April 2023

Response to vaccines in WT type and PI3K-delta KO mice
Supplemental Fig. 1 from Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
Authors: Abu Eid Rasha , Ahmad Shamim , Lin Yuan , Webb Mason , Berrong Zuzana , Shrimali Rajeev , Kumai Takumi , Ananth Sudha , Rodriguez Paulo C. , Celis Esteban , Janik John , Mkrtichyan Mikayel , Khleif Samir N.
Published: April 2023

PI3K-delta inhibition preserves memory phenotype (all conetrations)
Supplemental Figures 1-6 from GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity
Authors: Cichocki Frank , Valamehr Bahram , Bjordahl Ryan , Zhang Bin , Rezner Betsy , Rogers Paul , Gaidarova Svetlana , Moreno Stacey , Tuininga Katie , Dougherty Phillip , McCullar Valarie , Howard Peter , Sarhan Dhifaf , Taras Emily , Schlums Heinrich , Abbot Stewart , Shoemaker Daniel , Bryceson Yenan T. , Blazar Bruce R. , Wolchko Scott , Cooley Sarah , Miller Jeffrey S.
Published: April 2023

This supplementary file contains Supplemental Figures 1-6. Supplemental Figure 1 shows that 7-day ex vivo culture of NK cells with IL-15 and 5 μM CHIR99021 leads to an increase in the frequencies of NK cells with heterogeneous adaptive NK cell phenotypes (defined by expression of CD57, PLZF, SYK and FcεR1γ) relative to DMSO controls. Supplemental Figure 2 contains a detailed phenotypic characterization of receptor expression and cytotoxic granule component levels in sorted CD3-CD56dimCD57- and CD3-CD56dimCD57+ NK cells cultured for 7 days with IL-15 and either DMSO or 5 μM CHIR99021. Supplementary Figure 3 shows an analysis of NK cell phenotype, viability and proliferation after 7-day culture with IL-15 and either DMSO or CHIR99021 at several concentrations (1 μM, 3 μM and 5 μM). Supplemental Figure 4 shows an analysis of NK cell function (CD107a and IFN-γ) against K562 cells. NK cells were cultured for 7 days in IL-15 and either DMSO or 5 μM CHIR99021. Function was determined for individual CD3-CD56+ NK cell subsets gated on CD57 and NKG2C. Supplemental Figure 5 shows an analysis of NK cell function (CD107a and IFN-γ) against K562 cells. NK cells were cultured for 7 days in IL-15 and either DMSO or 5 μM CHIR99021. Function was determined for individual CD3-CD56+ NK cell subsets gated on CD57 and KIR. Supplemental Figure 6 shows the frequency of ex vivo expanded NK cells expressing CD57 and/or NKG2C 14 days after adoptive transfer into NSG mice.
Supplementary Information from Nrf2 Mutagenic Activation Drives Hepatocarcinogenesis
Authors: Ngo Hoang Kieu Chi , Kim Do-Hee , Cha Young-Nam , Na Hye-Kyung , Surh Young-Joon
Published: April 2023

Supplementary Materials and Methods. Supplementary figures: Figure S1. Genotyping of WT and Nrf2 KO mice; Figure S2. Nrf2 KO mice do not exhibit hepatic anomalies; Figure S3. Glut1 is upregulated by Nrf2 in the livers of DEN-treated mice; Figure S4. Nrf2 induces upregulation of hepatic antioxidant gene expression in the DEN-treated mice; Figure S5. Mutations in Nrf2 are associated with an inferior survival. Supplementary tables: Table S1. The sequences of primers used for genotyping; Table S2. The sequences of primers used for qPCR; Table S3. The primers used for identifying mutations in Nrf2; Table S4. The sequences of primers used for constructing plasmids and site-directed mutagenesis study.
Supplementary Figure 5 from Distinct Roles of HES1 in Normal Stem Cells and Tumor Stem-like Cells of the Intestine
Authors: Goto Norihiro , Ueo Taro , Fukuda Akihisa , Kawada Kenji , Sakai Yoshiharu , Miyoshi Hiroyuki , Taketo Makoto Mark , Chiba Tsutomu , Seno Hiroshi
Published: April 2023

Hes1 deletion in Lgr5+ TSCs suppresses tumor spheroid growth.
Supplementary Figure 3 from Distinct Roles of HES1 in Normal Stem Cells and Tumor Stem-like Cells of the Intestine
Authors: Goto Norihiro , Ueo Taro , Fukuda Akihisa , Kawada Kenji , Sakai Yoshiharu , Miyoshi Hiroyuki , Taketo Makoto Mark , Chiba Tsutomu , Seno Hiroshi
Published: April 2023

Hes1 deletion in Lgr5+ NSCs does not affect proliferative capacity or secretory differentiation of normal intestinal epithelium.
Supplementary Figures S1-S8; Supplementary Tables S1-S8; Supplementary methods from De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer
Authors: Tadros Saber , Shukla Surendra K. , King Ryan J. , Gunda Venugopal , Vernucci Enza , Abrego Jaime , Chaika Nina V. , Yu Fang , Lazenby Audrey J. , Berim Lyudmyla , Grem Jean , Sasson Aaron R. , Singh Pankaj K.
Published: April 2023

Figure S1: FASN inhibition with orlistat shows synergistic activity with gemcitabine in AsPC-1 cells; Figure S2: Effect of orlistat on the lipid content of pancreatic cancer cells; Figure S3: Platensimycin shows synergistic activity with gemcitabine in AsPC-1 cells; Figure S4: Lipid synthesis inhibitor C75 improves the effect of gemcitabine in pancreatic cancer cell lines; Figure S5: Lipid synthesis inhibitor fatostatin improves the effect of gemcitabine in pancreatic cancer cell lines; Figure S6: Albumin-conjugated palmitate does not rescue the anti-proliferative effects of gemcitabine; Figure S7: AdCM does not rescue the antiproliferative effect of gemcitabine on pancreatic cancer cells under the regular and stress conditions; Figure S8: Effect of AdCM on the lipid content of pancreatic cancer cells. Table S1: Metabolic pathway enrichment in pancreatic ductal adenocarcinoma patients treated with gemcitabine (data pooled from TCGA); Table S2: Patient Characteristics for Figure 1D; Table S3: Cell line gemcitabine responsiveness (IC50), FASN expression, and mutation status; Table S4: Orlistat responsiveness in pancreatic cancer cell lines; Table S5: Combination index of gemcitabine and orlistat in pancreatic cancer cell lines PANC-1, AsPC-1, Capan-1, and HPAF-II; Table S6: Combination index of gemcitabine and C75 in pancreatic cancer cell lines PANC-1, and AsPC-1; Table S7: Combination index of gemcitabine and fatostatin in pancreatic cancer cell lines PANC-1, and AsPC-1; Table S8: Combination index of gemcitabine and thapsigargin in pancreatic cancer cell lines PANC-1. SUPPLEMENTARY MATERIALS AND METHODS
Supplemental figure 9 from Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Authors: Bui Mai H. , Lin Xiaoyu , Albert Daniel H. , Li Leiming , Lam Lloyd T. , Faivre Emily J. , Warder Scott E. , Huang Xiaoli , Wilcox Denise , Donawho Cherrie K. , Sheppard George S. , Wang Le , Fidanze Steve , Pratt John K. , Liu Dachun , Hasvold Lisa , Uziel Tamar , Lu Xin , Kohlhapp Fred , Fang Guowei , Elmore Steven W. , Rosenberg Saul H. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

ABBV-075 inhibits genes that are important for cell cycle
Supplemental figure 7 & 8 from Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Authors: Bui Mai H. , Lin Xiaoyu , Albert Daniel H. , Li Leiming , Lam Lloyd T. , Faivre Emily J. , Warder Scott E. , Huang Xiaoli , Wilcox Denise , Donawho Cherrie K. , Sheppard George S. , Wang Le , Fidanze Steve , Pratt John K. , Liu Dachun , Hasvold Lisa , Uziel Tamar , Lu Xin , Kohlhapp Fred , Fang Guowei , Elmore Steven W. , Rosenberg Saul H. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

BET inhibitor causes cell cycle arrest and triggers senescence in solid tumor cells
Figure S3 from β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy
Authors: Bucsek Mark J. , Qiao Guanxi , MacDonald Cameron R. , Giridharan Thejaswini , Evans Lauren , Niedzwecki Brian , Liu Haichao , Kokolus Kathleen M. , Eng Jason W.-L. , Messmer Michelle N. , Attwood Kristopher , Abrams Scott I. , Hylander Bonnie L. , Repasky Elizabeth A.
Published: April 2023

This figure shows that the data we presented in Figure 3 of the paper for IFNy and T-bet is not tumor model specific, and that these observations were also made in CD8+ TILs form 4T1 tumors.
Figure S2 from β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy
Authors: Bucsek Mark J. , Qiao Guanxi , MacDonald Cameron R. , Giridharan Thejaswini , Evans Lauren , Niedzwecki Brian , Liu Haichao , Kokolus Kathleen M. , Eng Jason W.-L. , Messmer Michelle N. , Attwood Kristopher , Abrams Scott I. , Hylander Bonnie L. , Repasky Elizabeth A.
Published: April 2023

This figure shows that we do not see differences in either the frequency or relative number of total CD8+ T cells or tetramer+ cells. This figure supports our conclusion that we observe differences in CD8+ T cells with an effector phenotype.
Figure S2 from Intestine-Specific Homeobox Gene ISX Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression
Authors: Wang Li-Ting , Chiou Shyh-Shin , Chai Chee-Yin , Hsi Edward , Yokoyama Kazunari K. , Wang Shen-Nien , Huang Shau-Ku , Hsu Shih-Hsien
Published: April 2023

Figure S2, AHR signals positively activated ISX expression in hepatoma cells. A, Relative mRNA expression levels of CYP1B1 and ISX in Hep 3B and SK-Hep1 cells with AHR overexpression as detected by semi-quantitative RT-PCR. Data are presented as means {plus minus} S.D. a, p < 0.001. B, Relative mRNA expression levels of CYP1B1 and ISX in Huh 7 and SK-Hep1 cells with treated with AHR ligand, TCDD (5 nM) were detected by semi-quantitative RT-PCR. C, Western blotting analysis of ISX proteins in SK-Hep1 cells transfected with AHR, ARNT or AHR-ARNT complex D, AHR transcriptionally activated luciferase activity driven by promoters of ISX in SK-Hep1 cells. Relative luciferase activity was calculated as described in the Supplemental Materials and Methods. E, Western blotting analysis of ISX, IDOs, KYNU and downstream gene, CYP 1B1 proteins in Huh 7 and SK-Hep1 cells transfected with knockdown vector shRNAi against AHR. F, Schematic presentation of a series of luciferase deletions of ISX promoter. Relative luciferase activity in SK-Hep1 was calculated as described in the Materials and methods section. G, Chromatin was prepared and immunoprecipitated with anti-AHR antibody from SK-Hep1 and Huh7 cells treated with TCDD. H, The promoter regions of ISX with AHR-binding element (XRE) deletion were not pulled down by the anti-AHR antibody. I, Western blotting analysis of ISX, IDO1, IDO2, CYP1B1 and TDO2 expression in hepatocytes of AHR+/+, AHR+/â^'and AHR-/â^' mice.
Supplemental figure 12 from Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Authors: Bui Mai H. , Lin Xiaoyu , Albert Daniel H. , Li Leiming , Lam Lloyd T. , Faivre Emily J. , Warder Scott E. , Huang Xiaoli , Wilcox Denise , Donawho Cherrie K. , Sheppard George S. , Wang Le , Fidanze Steve , Pratt John K. , Liu Dachun , Hasvold Lisa , Uziel Tamar , Lu Xin , Kohlhapp Fred , Fang Guowei , Elmore Steven W. , Rosenberg Saul H. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

PP2A activator PTZ does not enhance ABBV-075 induced apoptosis in solid tumor cell lines
Supplemental figure 10 & 11 from Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Authors: Bui Mai H. , Lin Xiaoyu , Albert Daniel H. , Li Leiming , Lam Lloyd T. , Faivre Emily J. , Warder Scott E. , Huang Xiaoli , Wilcox Denise , Donawho Cherrie K. , Sheppard George S. , Wang Le , Fidanze Steve , Pratt John K. , Liu Dachun , Hasvold Lisa , Uziel Tamar , Lu Xin , Kohlhapp Fred , Fang Guowei , Elmore Steven W. , Rosenberg Saul H. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

ABBV-075 inhibits Bcl-XL transcription and displace BRD4 from Bcl-XL regulatory regions
'Supplemental figure 2 from Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Authors: Bui Mai H. , Lin Xiaoyu , Albert Daniel H. , Li Leiming , Lam Lloyd T. , Faivre Emily J. , Warder Scott E. , Huang Xiaoli , Wilcox Denise , Donawho Cherrie K. , Sheppard George S. , Wang Le , Fidanze Steve , Pratt John K. , Liu Dachun , Hasvold Lisa , Uziel Tamar , Lu Xin , Kohlhapp Fred , Fang Guowei , Elmore Steven W. , Rosenberg Saul H. , McDaniel Keith F. , Kati Warren M. , Shen Yu
Published: April 2023

Induction of apoptosis across cancer cell lines and CD34 normal cells
Supplementary Fig. 4. from HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas
Authors: Sun Mianen , Tong Pan , Kong Wen , Dong Baijun , Huang Yiran , Park In Young , Zhou Lijun , Liu Xian-De , Ding Zhiyong , Zhang Xuesong , Bai Shanshan , German Peter , Powell Reid , Wang Quan , Tong Xuefei , Tannir Nizar M. , Matin Surena F. , Rathmell W. Kimryn , Fuller Gregory N. , McCutcheon Ian E. , Walker Cheryl L. , Wang Jing , Jonasch Eric
Published: April 2023

Postulated HNF1B consensus-binding sequences in Mad1l1, Mad2l1, Bub1b, Rb1 and Cdkn1b genes and affected postulated substrates' chromatin access after depletion of Hnf1b.
Figure S2 from Targeting SRC Coactivators Blocks the Tumor-Initiating Capacity of Cancer Stem-like Cells
Authors: Rohira Aarti D. , Yan Fei , Wang Lei , Wang Jin , Zhou Suoling , Lu Andrew , Yu Yang , Xu Jianming , Lonard David M. , O'Malley Bert W.
Published: April 2023

Figure S2 shows that treatment of breast cancer cells with SI-2 reduces SRCs protein expression
Supplementary Table 1 from EpCAM Inhibition Sensitizes Chemoresistant Leukemia to Immune Surveillance
Authors: Zheng Xiaohu , Fan Xiaolei , Fu Binqing , Zheng Meijuan , Zhang Aimei , Zhong Kai , Yan Jialai , Sun Rui , Tian Zhigang , Wei Haiming
Published: April 2023

Clinical characteristics of leukemic patients in this study
Supplemental section from SIRT3-Mediated Dimerization of IDH2 Directs Cancer Cell Metabolism and Tumor Growth
Authors: Zou Xianghui , Zhu Yueming , Park Seong-Hoon , Liu Guoxiang , O'Brien Joseph , Jiang Haiyan , Gius David
Published: April 2023

Figure S1. Starvation decreased mitochondrial acetylation in MCF7 cells; Figure S2. The image of all harvested tumors from immunodeficient mice injected with MCF-shIDH2-IDH2WT, MCF7-shIDH2-IDH2K413R and MCF7-shIDH2-IDH2K413Q cells were presented; Figure S3. Co-expression of IDH2K413Q with Myc or oncogenic RasG12D increases the invasiveness of NIH3T3 cells in soft agar colony formation assay; Figure S4. Quantification of colony sizes (n=4); Figure S5. Exogenous alpha-ketoglutarate or isocitrate alters clonogenic growth and switches cancer cell metabolism in vitro; Figure S6. Decreased production of ROS by mitoTEMPO decreased clonogenic survival of MCF7-shIDH2-IDH2K413Q cells in vitro; Figure S7. Acetylation of IDH2 negatively correlate with SIRT3 protein levels in breast cancer patient samples
Tables S1-3 from Risk of Second Malignancies in Solid Organ Transplant Recipients Who Develop Keratinocyte Cancers
Authors: Zamoiski Rachel D. , Yanik Elizabeth , Gibson Todd M. , Cahoon Elizabeth K. , Madeleine Margaret M. , Lynch Charles F. , Gustafson Sally , Goodman Marc T. , Skeans Melissa , Israni Ajay K. , Engels Eric A. , Morton Lindsay M.
Published: April 2023

This file includes Supplementary tables describing 1) Concordance of Medicare claims and SRTR malignancy reports, 2011-2013; 2) SEER diagnosis codes and groupings; and 3) Hazard ratios for selected SEER diagnoses by diagnosis of KC among 118,440 solid organ transplant recipients.
Figure S3 from Acetylation of Mastermind-like 1 by p300 Drives the Recruitment of NACK to Initiate Notch-Dependent Transcription
Authors: Jin Ke , Zhou Wen , Han Xiaoqing , Wang Zhiqiang , Li Bin , Jeffries Shawn , Tao Wensi , Robbins David J. , Capobianco Anthony J.
Published: April 2023

esophageal adenocarcinoma is sensitive to p300/CBP inhibitor
Supplementary methods and figures from Unpaired Extracellular Cysteine Mutations of CSF3R Mediate Gain or Loss of Function
Authors: Zhang Haijiao , Means Sophie , Schultz Anna Reister , Watanabe-Smith Kevin , Medeiros Bruno C. , Bottomly Daniel , Wilmot Beth , McWeeney Shannon K. , Kükenshöner Tim , Hantschel Oliver , Tyner Jeffrey W.
Published: April 2023

This file contains additional data such as detailed sequencing methods; Sanger sequencing result; receptor expression and function of R308 and double cysteine mutations.
Supplementary Figures from JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity
Authors: Ye Juan , Li Tian-Sheng , Xu Gang , Zhao Yi-Ming , Zhang Ning-Ping , Fan Jia , Wu Jian
Published: April 2023

Figure S1 showed the effect of JCAD on LATS2 interaction with Mob and on TAZ Figure S2 showed expression and function of JCAD recovery in JCAD-KD cells Figure S3 showed YAP and p-YAP levels in cytosolic and nuclear fractions of JCAD-KD and control cells Figure S4 showed liver mRNA levels of core components of the Hippo signal pathway (LAST2, MST1/2, MOB1A/B, YAP, TAZ, CCND1) in different stages (five, nine and twelve months) of high fat/Calorie plus high fructose/glucose feeding in mice (n=3 in each group)
Supplemental Materials from 3D Mathematical Modeling of Glioblastoma Suggests That Transdifferentiated Vascular Endothelial Cells Mediate Resistance to Current Standard-of-Care Therapy
Authors: Yan Huaming , Romero-López Mónica , Benitez Lesly I. , Di Kaijun , Frieboes Hermann B. , Hughes Christopher C.W. , Bota Daniela A. , Lowengrub John S.
Published: April 2023

The nondimensionalization of the mathematical model, model parameters, and detailed analysis of the results in Main Text, including 2D slices and volume fractions of each cell type in Control and tumors treated by anti-angiogenic, anti-mitotic, differentiation and anti-GEC therapies individually or combinatorically.
Spplementary table 1 from Loss of FAM46C Promotes Cell Survival in Myeloma
Authors: Zhu Yuan Xiao , Shi Chang-Xin , Bruins Laura A. , Jedlowski Patrick , Wang Xuewei , Kortüm K. Martin , Luo Moulun , Ahmann Jonathan M. , Braggio Esteban , Stewart A. Keith
Published: April 2023

The primers used to generate FAM46C mutants. DNA oligos were synthesized for generating FAM46C mutants.
Supplementary Figures S1-22 from Variability in Chromatin Architecture and Associated DNA Repair at Genomic Positions Containing Somatic Mutations
Authors: Lim Byungho , Mun Jihyeob , Kim Yong Sung , Kim Seon-Young
Published: April 2023

Supplementary Figure S1 shows the distribution of chromatin features around mutations across multiple cancer types. Sup S2 and S3 shows the average signal distributions of nucleosome occupancy across several cancer types. Sup S4 shows correlation between histone modifications and mutation rates of indels and SNVs. Sup S5 shows mutation rates in intragenic enhancer relative to non-enhancer Sup S6 shows the relative cumulative frequencies of missense and silent SNVs. Sup S7, S8, S9, S10 shows counts of each of the four indel types across multiple cancer types. Sup S11 shows the average signal distributions of DNA methylation around mutation positions. Sup S12, S13, S14, S15 shows the average signal distribution of a few histone marks and nucleosomes around SNV and indel positions in several tumor types. Sup S16 shows the binding pattern of NER machineries around mutation positions. Sup S17 shows the average distribution of H3K3me3, XPB, and XPD around indel positions from STAD. Sup S18 shows the average distributions of CSB and Pol II around a few TFBS. Sup S19 shows NER activity around mutations. Sup S20 shows relationship between mutation acquisition and chromatin features in MMR- and POLE-deficient tumors. Sup S21 summarizes epigenomic features that distinguish SNVs, indels, and non-mutated positions. Sup S22 shows the signal intensity of TC-NER on 12 types of missense SNVs
Supplementary Data from MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway
Authors: Tripathi Satyendra C. , Fahrmann Johannes F. , Celiktas Muge , Aguilar Mitzi , Marini Kieren D. , Jolly Mohit K. , Katayama Hiroyuki , Wang Hong , Murage Eunice N. , Dennison Jennifer B. , Watkins D. Neil , Levine Herbert , Ostrin Edwin J. , Taguchi Ayumu , Hanash Samir M.
Published: April 2023

Contains supplementary methods (Gene knockdown and overexpression, Sample preparation and mass spectrometric analysis, BrdU assay, Immunoblotting, Mathematical modeling for regulation of MCAM), supplementary references and supplementary figure legends
Supplemental Figure 3 from Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer
Authors: Barton Valerie N. , Christenson Jessica L. , Gordon Michael A. , Greene Lisa I. , Rogers Thomas J. , Butterfield Kiel , Babbs Beatrice , Spoelstra Nicole S. , D'Amato Nicholas C. , Elias Anthony , Richer Jennifer K.
Published: April 2023

Paclitaxel and enzalutamide combination treatment.
supplemental text from Epstein–Barr Virus-Induced VEGF and GM-CSF Drive Nasopharyngeal Carcinoma Metastasis via Recruitment and Activation of Macrophages
Authors: Huang Di , Song Shi-Jian , Wu Zi-Zhao , Wu Wei , Cui Xiu-Ying , Chen Jia-Ning , Zeng Mu-Sheng , Su Shi-Cheng
Published: April 2023

supplemental text includes supplemental figure legend, supplemental experimental procedures and supplemental reference.
Supplementary Figure 2 from Monitoring the Vascular Response and Resistance to Sunitinib in Renal Cell Carcinoma In Vivo with Susceptibility Contrast MRI
Authors: Robinson Simon P. , Boult Jessica K.R. , Vasudev Naveen S. , Reynolds Andrew R.
Published: April 2023

Individual growth kinetics for 786-0-R RCC xenografts exhibiting acquired resistance to sunitinib, and pathological confirmation of the abundant vasculature in untreated, progressing 786-0 xenografts.
Figure S7 from Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair
Authors: Piacente Francesco , Caffa Irene , Ravera Silvia , Sociali Giovanna , Passalacqua Mario , Vellone Valerio G. , Becherini Pamela , Reverberi Daniele , Monacelli Fiammetta , Ballestrero Alberto , Odetti Patrizio , Cagnetta Antonia , Cea Michele , Nahimana Aimable , Duchosal Michel , Bruzzone Santina , Nencioni Alessio
Published: April 2023

Figure S7 shows that 2-hydroxynicotinate sodium salt (2-HNANa) effectively sensitizes OVCAR-5 cells to FK866.
Figure S6 from Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair
Authors: Piacente Francesco , Caffa Irene , Ravera Silvia , Sociali Giovanna , Passalacqua Mario , Vellone Valerio G. , Becherini Pamela , Reverberi Daniele , Monacelli Fiammetta , Ballestrero Alberto , Odetti Patrizio , Cagnetta Antonia , Cea Michele , Nahimana Aimable , Duchosal Michel , Bruzzone Santina , Nencioni Alessio
Published: April 2023

Figure S6 shows that NAPRT overexpression confers resistance to FK866 to MIA PaCa2 cells, but resistance is reverted by 2-HNA.
Table S5 from Competition between DNA Methylation, Nucleotide Synthesis, and Antioxidation in Cancer versus Normal Tissues
Authors: Cao Sha , Zhu Xiwen , Zhang Chi , Qian Hong , Schuttler Heinz-Bernd , Gong Jianping , Xu Ying
Published: April 2023

The list of genes encoding all the enzymes transporters.
Supplemental table 2 from ATOH1 Promotes Leptomeningeal Dissemination and Metastasis of Sonic Hedgehog Subgroup Medulloblastomas
Authors: Grausam Katie B. , Dooyema Samuel D.R. , Bihannic Laure , Premathilake Hasitha , Morrissy A. Sorana , Forget Antoine , Schaefer Amanda M. , Gundelach Justin H. , Macura Slobodan , Maher Diane M. , Wang Xin , Heglin Alex H. , Ge Xijin , Zeng Erliang , Puget Stephanie , Chandrasekar Indra , Surendran Kameswaran , Bram Richard J. , Schüller Ulrich , Talyor Michael D. , Ayrault Olivier , Zhao Haotian
Published: April 2023

This table provides supplemental information on the results of MetaCore enrichment analysis of differentially expressed genes (FDR<0.05) between tumors in Ptch1+/- and MAP mice and adult wild type cerebellum.
Supplementary Material from Highly Accurate Detection of Cancer In Situ with Intraoperative, Label-Free, Multimodal Optical Spectroscopy
Authors: Jermyn Michael , Mercier Jeanne , Aubertin Kelly , Desroches Joannie , Urmey Kirk , Karamchandiani Jason , Marple Eric , Guiot Marie-Christine , Leblond Frederic , Petrecca Kevin
Published: April 2023

Contains a table showing prominent Raman peaks for molecular species; Figures showing pathology images, Raman spectra, and boxplots of Fluorescence & Raman Peaks; Data processing methods for fluorescence and diffuse reflectance.
Supplementary Figure S3. from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Authors: Borriello Lucia , Nakata Rie , Sheard Michael A. , Fernandez G. Esteban , Sposto Richard , Malvar Jemily , Blavier Laurence , Shimada Hiroyuki , Asgharzadeh Shahab , Seeger Robert C. , DeClerck Yves A.
Published: April 2023

CAF-MSC increase tumor engraftment and growth in xenograft model.
Figure S5 from Tumor-Associated Macrophages Promote Malignant Progression of Breast Phyllodes Tumors by Inducing Myofibroblast Differentiation
Authors: Nie Yan , Chen Jianing , Huang Di , Yao Yandan , Chen Jiewen , Ding Lin , Zeng Jiayi , Su Shicheng , Chao Xue , Su Fengxi , Yao Herui , Hu Hai , Song Erwei
Published: April 2023

HGF was highly secreted by malignant PT cells and induced the CCL18 production from TAMs.
Figure S4-S6 from Normal and Malignant Cells Exhibit Differential Responses to Calcium Electroporation
Authors: Frandsen Stine K. , Krüger Mie B. , Mangalanathan Uma M. , Tramm Trine , Mahmood Faisal , Novak Ivana , Gehl Julie
Published: April 2023

Figure S4. Effect on skin above tumors treated with calcium electroporation MDA-MB231 (human breast cancer) tumors treated with different doses of calcium electroporation: 168 mM CaCl2 injected in a volume equivalent to 20% - 80% of tumor volume and 100 - 500 mM CaCl2 injected in a volume equivalent to half the tumor volume. Skin above the treated tumors was removed 2 days after treatment. EP = electroporation. Inflammation in dermis/subcutis and extravasation of erythrocytes in dermis were scored. Percent of sections in each scoring group and linear regression of mean in each dosing group are shown, n = 4-5 for treated and n = 3 for untreated/sham treated. Figure S5. Effect on muscle below tumors treated with calcium electroporation MDA-MB231 (human breast cancer) tumors treated with different doses of calcium electroporation: 168 mM CaCl2 injected in a volume equivalent to 20-80% of tumor volume and 100-500 mM CaCl2 injected in a volume equivalent to half the tumor volume. Muscle below the treated tumors was removed 2 days after treatment. EP = electroporation. Fraction of necrosis was estimated and shown as mean + SD. Necrosis, regenerative changes, and inflammation were scored and shown as percent of sections in each scoring group. Linear regression of mean in each dosing group are shown, n = 3-5 for treated and n = 3 for untreated/sham treated. Figure S6. Effect on muscle tissue treated directly with calcium electroporation Muscle tissue (6 x 10 mm) on the flank of nude mice were treated with 168 mM CaCl2 or physiological saline injection in a volume equivalent to 50% of tissue volume followed by electroporation (EP) or not. The muscle tissue was removed two days after treatment. Fraction of necrosis was estimated and shown as mean + SD. n=5-6.
Figure S2 from Normal and Malignant Cells Exhibit Differential Responses to Calcium Electroporation
Authors: Frandsen Stine K. , Krüger Mie B. , Mangalanathan Uma M. , Tramm Trine , Mahmood Faisal , Novak Ivana , Gehl Julie
Published: April 2023

Figure S2. Light microscope image of colon cancer tumor treated with calcium electroporation HT29 (human colon cancer) tumor treated with 168 mM calcium electroporation and removed 6 days after treatment. Light microscope image of HE section of tumor showing healing of the tumor with replacement of connective tissue in the central/upper left area of the image, a small area of necrosis in the lower left corner, and vital tumor tissue in the right side of the image.
Supplementary Figure 1 from Mitochondrial Superoxide Increases Age-Associated Susceptibility of Human Dermal Fibroblasts to Radiation and Chemotherapy
Authors: Mapuskar Kranti A. , Flippo Kyle H. , Schoenfeld Joshua D. , Riley Dennis P. , Strack Stefan , Hejleh Taher Abu , Furqan Muhammad , Monga Varun , Domann Frederick E. , Buatti John M. , Goswami Prabhat C. , Spitz Douglas R. , Allen Bryan G.
Published: April 2023

Molecular structure of SOD mimetic, characterization of young and old dermal fibroblasts, and sensitivity of young and old dermal fibroblasts to cancer therapies.
Supplementary Table 7 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
Authors: Wali Vikram B. , Langdon Casey G. , Held Matthew A. , Platt James T. , Patwardhan Gauri A. , Safonov Anton , Aktas Bilge , Pusztai Lajos , Stern David F. , Hatzis Christos
Published: April 2023

Low-throughput validation dataset.
Supplementary Figures 1 through 9 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
Authors: Wali Vikram B. , Langdon Casey G. , Held Matthew A. , Platt James T. , Patwardhan Gauri A. , Safonov Anton , Aktas Bilge , Pusztai Lajos , Stern David F. , Hatzis Christos
Published: April 2023

Supplementary Figure 1. Effect of panel A drugs on TNBC cell growth in 96-well format. Supplementary Figure 2. Effect of panel B drugs alone and in combination with panel A drugs on TNBC cell growth. Supplementary Figure 3. Summary of growth inhibition by pairwise drug combinations. Supplementary Figure 4. Hierarchical clustering of cell lines based on response to drug treatments and based on expression of drug targets. Supplementary Figure 5. Principal component analysis to associate patterns of target expression with patterns of drug response. Supplementary Figure 6. Assessment of superadditivity of drug combinations. Supplementary Figure 7. A: Comparison of crizotinib versus XL-184 dose response curves when combined with ABT-263 in the six TNBC cell lines. Supplementary Figure 8. ABT-263 and crizotinib induce apoptosis in TNBC cells. Supplementary Figure 9. Expression of MET and AXL in a cohort of 59 TNBC samples from the TCGA breast cancer cohort relative to the median expression of each gene in all breast cancer samples in TCGA.
Table S1 from Loss of Igf2 Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth
Authors: Damaschke Nathan A. , Yang Bing , Bhusari Sachin , Avilla Mele , Zhong Weixiong , Blute Michael L. , Huang Wei , Jarrard David F.
Published: April 2023

Supplementary Table S1 details the list of primers and their sequence used in this study.
Supplementary Figures 1 through 8 from mda-7/IL-24 Mediates Cancer Cell–Specific Death via Regulation of miR-221 and the Beclin-1 Axis
Authors: Pradhan Anjan K. , Talukdar Sarmistha , Bhoopathi Praveen , Shen Xue-Ning , Emdad Luni , Das Swadesh K. , Sarkar Devanand , Fisher Paul B.
Published: April 2023

Supplementary Figure 1: miRNA expression in MDA-MB-231 cells infected with either Ad.null or Ad.mda-7. Supplementary Figure 2: miR 221 expression in normal cell lines Supplementary Figure 3: miR 221 expression and ROS production following treatment with ROS inducers. Supplementary Figure 4: Beclin-1 expression in miR-221 or anti-miR-221 treated cells. Supplementary Figure 5: Beclin-1, p27, and PUMA expression in anti-miR-221 treated cells. Supplementary Figure 6: Beclin-1 expression in Rapamycin and /or miR-221 treated cells. Supplementary Figure 7: Quantification of MDA-7/IL-24 and Beclin-1 in immunohistochemistry images. Supplementary Figure 8: Immunohistochemical analysis of p27 and PUMA in tumor sections.
Fig.S1 to S7 from CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy
Authors: Turcotte Martin , Allard David , Mittal Deepak , Bareche Yacine , Buisseret Laurence , José Vinu , Pommey Sandra , Delisle Vincent , Loi Sherene , Joensuu Heikki , Kellokumpu-Lehtinen Pirkko-Liisa , Sotiriou Christos , Smyth Mark J. , Stagg John
Published: April 2023

Fig.S1: CD73 prognosis in untreated breast cancer; Fig. S2: CD73 prognosis in METABRIC; Fig. S3: Multivariate analysis; Fig. S4: CD73 expression in H2N100 and TUBO; Fig. S5: H2N100 and TUBO survival data; Fig. S6: Combined treatment in NRG mice; Fig. S7: CD73 and EMT correlations
Supplementary Figure Legends from mda-7/IL-24 Mediates Cancer Cell–Specific Death via Regulation of miR-221 and the Beclin-1 Axis
Authors: Pradhan Anjan K. , Talukdar Sarmistha , Bhoopathi Praveen , Shen Xue-Ning , Emdad Luni , Das Swadesh K. , Sarkar Devanand , Fisher Paul B.
Published: April 2023

Figure legends for supplementary figures 1 to 8
Supplementary Figures and Tables from GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma
Authors: Kasiri Sahba , Shao Chunli , Chen Baozhi , Wilson Alexandra N. , Yenerall Paul , Timmons Brenda C. , Girard Luc , Tian Hui , Behrens Carmen , Wistuba Ignacio I. , Gazdar Adi F. , Kim James
Published: April 2023

This file contains additional data including additional mRNA analyses of TCGA and SPORE datasets, validation of antibodies and siRNAs, ATO dose finding studies, analyses of mutations in PI3K pathway in human cancers. The file also contains 2 tables of Taqman probe information and human and mouse specific qPCR primers.
Figure S1 from Kindlin-2 Regulates the Growth of Breast Cancer Tumors by Activating CSF-1–Mediated Macrophage Infiltration
Authors: Sossey-Alaoui Khalid , Pluskota Elzbieta , Bialkowska Katarzyna , Szpak Dorota , Parker Yvonne , Morrison Chevaun D. , Lindner Daniel J. , Schiemann William P. , Plow Edward F.
Published: April 2023

This figure contains tumor staining with individual markers to support Figure 3F and Figure 3I
Figure S5 from Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade
Authors: Ohs Isabel , Ducimetière Laura , Marinho Joana , Kulig Paulina , Becher Burkhard , Tugues Sonia
Published: April 2023

Expression of PD-1 on lung NK cells from naïve and 4T1 tumor-bearing mice
Figure S2 from Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade
Authors: Ohs Isabel , Ducimetière Laura , Marinho Joana , Kulig Paulina , Becher Burkhard , Tugues Sonia
Published: April 2023

NK cell receptor repertoire in the circulation and the BM of 4T1 tumor-bearing mice
Supplementary data from Evolution of Cancer Stem-like Cells in Endocrine-Resistant Metastatic Breast Cancers Is Mediated by Stromal Microvesicles
Authors: Sansone Pasquale , Berishaj Marjan , Rajasekhar Vinagolu K. , Ceccarelli Claudio , Chang Qing , Strillacci Antonio , Savini Claudia , Shapiro Lauren , Bowman Robert L. , Mastroleo Chiara , De Carolis Sabrina , Daly Laura , Benito-Martin Alberto , Perna Fabiana , Fabbri Nicola , Healey John H. , Spisni Enzo , Cricca Monica , Lyden David , Bonafé Massimiliano , Bromberg Jacqueline
Published: April 2023

Supplementary Figures and Tables
Supplementary legends from New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome
Authors: Wilson Leah J. , Linley Adam , Hammond Dean E. , Hood Fiona E. , Coulson Judy M. , MacEwan David J. , Ross Sarah J. , Slupsky Joseph R. , Smith Paul D. , Eyers Patrick A. , Prior Ian A.
Published: April 2023

Supplementary legends
Supplementary Materials and Methods from Noncoding Effects of Circular RNA CCDC66 Promote Colon Cancer Growth and Metastasis
Authors: Hsiao Kuei-Yang , Lin Ya-Chi , Gupta Sachin Kumar , Chang Ning , Yen Laising , Sun H. Sunny , Tsai Shaw-Jenq
Published: April 2023

Supplementary Materials and Methods
Supplementary Figure S5. Localization of PLK1 during Mitosis. from Cervical Cancer Growth Is Regulated by a c-ABL–PLK1 Signaling Axis
Authors: Yang Xu , Chen Gang , Li Wei , Peng Changmin , Zhu Yue , Yang Xiaoming , Li Teng , Cao Cheng , Pei Huadong
Published: April 2023

A, HeLa cells transfected with indicated plasmids were fixed and subjected to double immunofluorescence staining with anti-PLK1 and anti-γ-Tubulin antibodies. DNA was stained with DAPI. Scale bar: 10 μm. B, Representative immunofluorescence imagines of HeLa cells with or without c-ABL inhibitor imatinib (10 μM, 24 hrs) treatment. Scale bar: 10 μm.
Supplementary Figures from The Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells
Authors: Jinesh Goodwin G. , Kamat Ashish M.
Published: April 2023

Supplementary figures 1-4 showing exit phase of blebbishield emergency program, K-Ras activation difference between RT4P and PBSHMS cells, tumorigenesis and metastasis of PBSHMS cells and detection of giant nuclei in metastatic tumor cells and in hepatosplenomegaly. This file also has legends for supplementary movies.
Supplementary Figure S2. Identification of PLK1 Tyrosine Phosphorylation Sites by c-ABL. from Cervical Cancer Growth Is Regulated by a c-ABL–PLK1 Signaling Axis
Authors: Yang Xu , Chen Gang , Li Wei , Peng Changmin , Zhu Yue , Yang Xiaoming , Li Teng , Cao Cheng , Pei Huadong
Published: April 2023

A, Identify the tyrosine phosphorylation sites on PLK1 by c-ABL. HEK293 cells were transfected with indicated plasmids. Cell lysates were immunoprecipitated with FLAG beads and immunoblotted as indicated. B, Alignments of the PLK1 consensus phosphorylation motif in c-ABL from human and other species.
Table S3 from Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Authors: Cejalvo Juan M. , Martínez de Dueñas Eduardo , Galván Patricia , García-Recio Susana , Burgués Gasión Octavio , Paré Laia , Antolín Silvia , Martinello Rosella , Blancas Isabel , Adamo Barbara , Guerrero-Zotano Ángel , Muñoz Montserrat , Nucíforo Paolo , Vidal María , Pérez Ramón M. , Chacón López-Muniz José I. , Caballero Rosalía , Peg Vicente , Carrasco Eva , Rojo Federico , Perou Charles M. , Cortés Javier , Adamo Vincenzo , Albanell Joan , Gomis Roger R. , Lluch Ana , Prat Aleix
Published: April 2023

Table
Figure S4 from Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Authors: Cejalvo Juan M. , Martínez de Dueñas Eduardo , Galván Patricia , García-Recio Susana , Burgués Gasión Octavio , Paré Laia , Antolín Silvia , Martinello Rosella , Blancas Isabel , Adamo Barbara , Guerrero-Zotano Ángel , Muñoz Montserrat , Nucíforo Paolo , Vidal María , Pérez Ramón M. , Chacón López-Muniz José I. , Caballero Rosalía , Peg Vicente , Carrasco Eva , Rojo Federico , Perou Charles M. , Cortés Javier , Adamo Vincenzo , Albanell Joan , Gomis Roger R. , Lluch Ana , Prat Aleix
Published: April 2023

Figure
Figure S1 from Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Authors: Cejalvo Juan M. , Martínez de Dueñas Eduardo , Galván Patricia , García-Recio Susana , Burgués Gasión Octavio , Paré Laia , Antolín Silvia , Martinello Rosella , Blancas Isabel , Adamo Barbara , Guerrero-Zotano Ángel , Muñoz Montserrat , Nucíforo Paolo , Vidal María , Pérez Ramón M. , Chacón López-Muniz José I. , Caballero Rosalía , Peg Vicente , Carrasco Eva , Rojo Federico , Perou Charles M. , Cortés Javier , Adamo Vincenzo , Albanell Joan , Gomis Roger R. , Lluch Ana , Prat Aleix
Published: April 2023

Figure
Supplementary Figure S2 from Enriching the Housing Environment for Mice Enhances Their NK Cell Antitumor Immunity via Sympathetic Nerve–Dependent Regulation of NKG2D and CCR5
Authors: Song Yanfang , Gan Yu , Wang Qing , Meng Zihong , Li Guohua , Shen Yuling , Wu Yufeng , Li Peiying , Yao Ming , Gu Jianren , Tu Hong
Published: April 2023

EE does not appear to influence the expression levels of the ligands of NKG2D and CCR5 in tumors.
Supplementary Video S1 from Tankyrase-Binding Protein TNKS1BP1 Regulates Actin Cytoskeleton Rearrangement and Cancer Cell Invasion
Authors: Ohishi Tomokazu , Yoshida Haruka , Katori Masamichi , Migita Toshiro , Muramatsu Yukiko , Miyake Mao , Ishikawa Yuichi , Saiura Akio , Iemura Shun-ichiro , Natsume Tohru , Seimiya Hiroyuki
Published: April 2023

Time-lapse imaging of HTC75 cells transfected with control siRNA.
Supporting Figures S5-S8 from Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate Cancer
Authors: Ponnusamy Suriyan , Coss Christopher C. , Thiyagarajan Thirumagal , Watts Kate , Hwang Dong-Jin , He Yali , Selth Luke A. , McEwan Iain J. , Duke Charles B. , Pagadala Jayaprakash , Singh Geetika , Wake Robert W. , Ledbetter Christopher , Tilley Wayne D. , Moldoveanu Tudor , Dalton James T. , Miller Duane D. , Narayanan Ramesh
Published: April 2023

S5: UT-155 prevents nuclear localization of AR and AR v567es. S6: UT-155 binds to AR AF-1 domain. S7: Results from microarray with SARDs.S8: UT-155 inhibits transactivation of AD1 and D567es AR transactivation. Metabolism properties of SARDs.
Supplementary Information from Tankyrase-Binding Protein TNKS1BP1 Regulates Actin Cytoskeleton Rearrangement and Cancer Cell Invasion
Authors: Ohishi Tomokazu , Yoshida Haruka , Katori Masamichi , Migita Toshiro , Muramatsu Yukiko , Miyake Mao , Ishikawa Yuichi , Saiura Akio , Iemura Shun-ichiro , Natsume Tohru , Seimiya Hiroyuki
Published: April 2023

Supplementary Material and Methods, Supplementary References, Supplementary Figure Legends, Supplementary Video Legends
Supplementary Figure S5 from Tankyrase-Binding Protein TNKS1BP1 Regulates Actin Cytoskeleton Rearrangement and Cancer Cell Invasion
Authors: Ohishi Tomokazu , Yoshida Haruka , Katori Masamichi , Migita Toshiro , Muramatsu Yukiko , Miyake Mao , Ishikawa Yuichi , Saiura Akio , Iemura Shun-ichiro , Natsume Tohru , Seimiya Hiroyuki
Published: April 2023

TNKS1BP1 is poly(ADP-ribosyl)ated by tankyrase but does not affect the telomeric function of tankyrase.
Supplementary Figure S3 from Tankyrase-Binding Protein TNKS1BP1 Regulates Actin Cytoskeleton Rearrangement and Cancer Cell Invasion
Authors: Ohishi Tomokazu , Yoshida Haruka , Katori Masamichi , Migita Toshiro , Muramatsu Yukiko , Miyake Mao , Ishikawa Yuichi , Saiura Akio , Iemura Shun-ichiro , Natsume Tohru , Seimiya Hiroyuki
Published: April 2023

Enhanced cofilin phosphorylation and actin dynamics in TNKS1BP1-depleted PANC-1 cells.
Supplemental Figure S6 from Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases
Authors: Ross Michael H. , Esser Alison K. , Fox Gregory C. , Schmieder Anne H. , Yang Xiaoxia , Hu Grace , Pan Dipanjan , Su Xinming , Xu Yalin , Novack Deborah V. , Walsh Thomas , Colditz Graham A. , Lukaszewicz Gabriel H. , Cordell Elizabeth , Novack Joshua , Fitzpatrick James A. J. , Waning David L. , Mohammad Khalid S. , Guise Theresa A. , Lanza Gregory M. , Weilbaecher Katherine N.
Published: April 2023

Micelle nanoparticle control treatment groups fail to attenuate bone metastases
Supplemental Figure S5 from Bone-Induced Expression of Integrin β3 Enables Targeted Nanotherapy of Breast Cancer Metastases
Authors: Ross Michael H. , Esser Alison K. , Fox Gregory C. , Schmieder Anne H. , Yang Xiaoxia , Hu Grace , Pan Dipanjan , Su Xinming , Xu Yalin , Novack Deborah V. , Walsh Thomas , Colditz Graham A. , Lukaszewicz Gabriel H. , Cordell Elizabeth , Novack Joshua , Fitzpatrick James A. J. , Waning David L. , Mohammad Khalid S. , Guise Theresa A. , Lanza Gregory M. , Weilbaecher Katherine N.
Published: April 2023

Hematologic analyses and visceral tumor burden analyses following DTX, micelle treatments
Supplemental Figure 1 from Sigma1 Targeting to Suppress Aberrant Androgen Receptor Signaling in Prostate Cancer
Authors: Thomas Jeffrey D. , Longen Charles G. , Oyer Halley M. , Chen Nan , Maher Christina M. , Salvino Joseph M. , Kania Blase , Anderson Kelsey N. , Ostrander William F. , Knudsen Karen E. , Kim Felix J.
Published: April 2023

Specificity of ARV7 and ARv567es antibodies.
Supplementary Figures 1-3 from Krüppel-like Transcription Factor KLF10 Suppresses TGFβ-Induced Epithelial-to-Mesenchymal Transition via a Negative Feedback Mechanism
Authors: Mishra Vivek Kumar , Subramaniam Malayannan , Kari Vijayalakshmi , Pitel Kevin S. , Baumgart Simon J. , Naylor Ryan M. , Nagarajan Sankari , Wegwitz Florian , Ellenrieder Volker , Hawse John R. , Johnsen Steven A.
Published: April 2023

Supplementary Figure S1 KLF10 is recruited to, and suppresses the expression of the FOSB gene. Supplementary Figure S2 ChIP analysis of KLF10 occupancy on the SNAI2 gene upon in control and TGFβ-stimulated Panc1 cells. Supplementary Figure S3 Heatmap for mRNA expression of CDH1, MMP7, CDH2 and MMP2 based on Cancer Cell Line Encyclopedia (CCLE) gene expression data in a panel of lung and pancreatic cancer cell lines.